(R)-N-(2-(ethylsulfonyl)ethyl)-2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-(1-(3-(4-hydroxyphenyl)-8-methyl-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-2-yl)ethyl)acetamide | 1010857-84-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-N-(2-(ethylsulfonyl)ethyl)-2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-(1-(3-(4-hydroxyphenyl)-8-methyl-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-2-yl)ethyl)acetamide
• CAS: 1010857-84-7
• 化学式: C₂₉H₃₂F₄N₄O₅S
• 分子量: 624.656
• InChiKey: BXWFJHQFHSDEQA-GOSISDBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.05
• 重原子数：
  43.0
• 可旋转键数：
  9.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  112.81
• 氢给体数：
  1.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  (R)-N-(2-(ethylsulfonyl)ethyl)-2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-(1-(3-(4-hydroxyphenyl)-8-methyl-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-2-yl)ethyl)acetamide 、 三氟甲磺酸酐 在 2,6-二甲基吡啶 作用下， 以 二氯甲烷 为溶剂， 以83%的产率得到(R)-4-(2-(1-(N-(2-(ethylsulfonyl)ethyl)-2-(4-fluoro-3-(trifluoromethyl)phenyl)acetamido)ethyl)-8-methyl-4-oxo-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-3(4H)-yl)phenyl trifluoromethanesulfonate
  参考文献：
  名称：

  Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists

  摘要：

  A series of six-six and six-five fused heterocyclic CXCR3 antagonists has been synthesized and their activities evaluated in an [I-125]-IP-10 displacement assay and an ITAC mediated in vitro cell migration assay. The pharmacokinetic properties of several top compounds have also been studied. This effort led to the discovery of compounds with increased potency and improved pharmacokinetic properties that could serve as useful tools to study the role of the CXCR3 receptor in vivo. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.060
• 作为产物：
  描述：

  (R)-N-(1-(3-(4-ethoxyphenyl)-8-methyl-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(2-(ethylsulfonyl)ethyl)-2-(4-fluoro-3-(trifluoromethyl)phenyl)acetamide 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 以71%的产率得到(R)-N-(2-(ethylsulfonyl)ethyl)-2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-(1-(3-(4-hydroxyphenyl)-8-methyl-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-2-yl)ethyl)acetamide
  参考文献：
  名称：

  Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists

  摘要：

  A series of six-six and six-five fused heterocyclic CXCR3 antagonists has been synthesized and their activities evaluated in an [I-125]-IP-10 displacement assay and an ITAC mediated in vitro cell migration assay. The pharmacokinetic properties of several top compounds have also been studied. This effort led to the discovery of compounds with increased potency and improved pharmacokinetic properties that could serve as useful tools to study the role of the CXCR3 receptor in vivo. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.060